Effective maintenance treatment with lenalidomide for a patient with aggressive adult T cell leukemia after chemotherapy

Effective maintenance treatment with lenalidomide for a patient with aggressive adult T cell leukemia after chemotherapy

Adult T cell leukemia/lymphoma (ATL) is incurable with conventional chemotherapies, and allogeneic stem cell transplantation (SCT) is the only curative treatment. Direct antitumor effects and antitumor immune responses are important factors that need to be considered in the treatment of ATL. A phase...

Full description

Bibliographic Details
Main Authors: Satoko Oka, Kazuo Ono, Masaharu Nohgawa
Format: Article
Language:English
Published: Elsevier 2019-01-01
Series:Leukemia Research Reports
Online Access:http://www.sciencedirect.com/science/article/pii/S2213048918300657
id doaj-f18a38f34475497382c56e510fe6eb8c
record_format Article
spelling doaj-f18a38f34475497382c56e510fe6eb8c2020-11-24T21:49:55ZengElsevierLeukemia Research Reports2213-04892019-01-01112123Effective maintenance treatment with lenalidomide for a patient with aggressive adult T cell leukemia after chemotherapySatoko Oka0Kazuo Ono1Masaharu Nohgawa2Division of Hematology, Japanese Red Cross Society Wakayama Medical Center, Wakayama, Wakayama, Japan; Corresponding author.Division of Pathology, Japanese Red Cross Society Wakayama Medical Center, Wakayama, JapanDivision of Hematology, Japanese Red Cross Society Wakayama Medical Center, Wakayama, Wakayama, JapanAdult T cell leukemia/lymphoma (ATL) is incurable with conventional chemotherapies, and allogeneic stem cell transplantation (SCT) is the only curative treatment. Direct antitumor effects and antitumor immune responses are important factors that need to be considered in the treatment of ATL. A phase II study reported long overall survival despite short progression-free survival in patients, implying that lenalidomide confers a survival benefit through immunomodulation for patients with ATL. We herein report that low-dose lenalidomide as maintenance therapy maintained a complete remission in a patient with aggressive ATL, whose condition has since remained stable with no recurrence for 24 months. Keywords: Lenalidomide, Adult T cell leukemia/ lymphoma (ATL), Maintenancehttp://www.sciencedirect.com/science/article/pii/S2213048918300657
collection DOAJ
language English
format Article
sources DOAJ
author Satoko Oka
Kazuo Ono
Masaharu Nohgawa
spellingShingle Satoko Oka
Kazuo Ono
Masaharu Nohgawa
Effective maintenance treatment with lenalidomide for a patient with aggressive adult T cell leukemia after chemotherapy
Leukemia Research Reports
author_facet Satoko Oka
Kazuo Ono
Masaharu Nohgawa
author_sort Satoko Oka
title Effective maintenance treatment with lenalidomide for a patient with aggressive adult T cell leukemia after chemotherapy
title_short Effective maintenance treatment with lenalidomide for a patient with aggressive adult T cell leukemia after chemotherapy
title_full Effective maintenance treatment with lenalidomide for a patient with aggressive adult T cell leukemia after chemotherapy
title_fullStr Effective maintenance treatment with lenalidomide for a patient with aggressive adult T cell leukemia after chemotherapy
title_full_unstemmed Effective maintenance treatment with lenalidomide for a patient with aggressive adult T cell leukemia after chemotherapy
title_sort effective maintenance treatment with lenalidomide for a patient with aggressive adult t cell leukemia after chemotherapy
publisher Elsevier
series Leukemia Research Reports
issn 2213-0489
publishDate 2019-01-01
description Adult T cell leukemia/lymphoma (ATL) is incurable with conventional chemotherapies, and allogeneic stem cell transplantation (SCT) is the only curative treatment. Direct antitumor effects and antitumor immune responses are important factors that need to be considered in the treatment of ATL. A phase II study reported long overall survival despite short progression-free survival in patients, implying that lenalidomide confers a survival benefit through immunomodulation for patients with ATL. We herein report that low-dose lenalidomide as maintenance therapy maintained a complete remission in a patient with aggressive ATL, whose condition has since remained stable with no recurrence for 24 months. Keywords: Lenalidomide, Adult T cell leukemia/ lymphoma (ATL), Maintenance
url http://www.sciencedirect.com/science/article/pii/S2213048918300657
work_keys_str_mv AT satokooka effectivemaintenancetreatmentwithlenalidomideforapatientwithaggressiveadulttcellleukemiaafterchemotherapy
AT kazuoono effectivemaintenancetreatmentwithlenalidomideforapatientwithaggressiveadulttcellleukemiaafterchemotherapy
AT masaharunohgawa effectivemaintenancetreatmentwithlenalidomideforapatientwithaggressiveadulttcellleukemiaafterchemotherapy
_version_ 1725886478005829632

Similar Items